Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP phenotype/genotype and chlordiazepoxide plasma levels in alcohol withdrawal
2021-002188-23Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Chlordiazepoxide in alcohol withdrawal syndrome (AWS), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Plasma concentration of chlordiazepoxide. Started May 2021; status: completed.
02
Drugs
Chlordiazepoxide
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on 2021-002188-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002188-23.